In Section A, contributors will receive diverse doses and schedules of oral ABBV-744 pill to identify Risk-free dosing program. Extra members will be enrolled on the discovered monotherapy dosign program. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 will likely be specified as "add-on" therapy. In Segment C, https://ariannar998epa1.celticwiki.com/user